TW202400572A - Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 - Google Patents

Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 Download PDF

Info

Publication number
TW202400572A
TW202400572A TW112111234A TW112111234A TW202400572A TW 202400572 A TW202400572 A TW 202400572A TW 112111234 A TW112111234 A TW 112111234A TW 112111234 A TW112111234 A TW 112111234A TW 202400572 A TW202400572 A TW 202400572A
Authority
TW
Taiwan
Prior art keywords
formula
compound
deuterium
prepare
pharmaceutical composition
Prior art date
Application number
TW112111234A
Other languages
English (en)
Chinese (zh)
Inventor
加里 德克雷森佐
馬丁 特瑞斯克
Original Assignee
美商生物醫學谷探索公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商生物醫學谷探索公司 filed Critical 美商生物醫學谷探索公司
Publication of TW202400572A publication Critical patent/TW202400572A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112111234A 2022-03-24 2023-03-24 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 TW202400572A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
US63/323,221 2022-03-24

Publications (1)

Publication Number Publication Date
TW202400572A true TW202400572A (zh) 2024-01-01

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112111234A TW202400572A (zh) 2022-03-24 2023-03-24 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
IL315702A (en) 2024-11-01
JP2025509969A (ja) 2025-04-11
CA3245978A1 (en) 2023-09-28
WO2023183905A3 (en) 2023-10-26
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
CN119212985A (zh) 2024-12-27
MX2024011415A (es) 2024-09-24

Similar Documents

Publication Publication Date Title
KR102725082B1 (ko) Fxr 효능제의 고체 형태
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
KR20100050466A (ko) 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
TW201925182A (zh) 磺醯胺化合物及其用途
AU2007310949A1 (en) Substituted indoles
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
US7772248B2 (en) Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
WO2007146124A2 (en) Deuterated tadalafil derivatives
FR2941948A1 (fr) Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
TW202400572A (zh) Erk的吡咯抑制劑之氘化類似物、其合成及其中間物
JP2004533448A (ja) インスリン抵抗性症候群及び糖尿病の治療のためのアデノシン類似体
US20070287734A1 (en) Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
HK40118078A (zh) Erk的吡咯抑制剂的氘代类似物、其合成及其中间体
CN117279923B (zh) 六元杂芳并脲环的衍生物及其应用
CN119053573A (zh) 氘代咪唑克生及其使用方法
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
JP7716147B2 (ja) 置換されたイソインドリン－１，３－ジオン類ｐｄｅ４阻害剤及びその薬物応用
KR101547407B1 (ko) 3-치환-6-(피리디닐메톡시)-피롤로피리딘 화합물
TWI692476B (zh) 環丁基-咪唑啶酮化合物
HK40113641A (zh) Fxr激动剂的固体形式
TW202517632A (zh) 氘代1,3二氫-2h-吲哚-2-酮衍生物
CN117700401A (zh) 一种氘代物及其在医药上的应用
HK40062091B (zh) Fxr激动剂的固体形式
CN118164979A (zh) 氮杂吲哚类PI3Kδ抑制剂、其制备方法和应用
HK40023760B (zh) 磺酰胺化合物及其用途